Taking tesamorelin for a year doesn't change blood sugar, insulin levels, or insulin resistance in obese people with low growth hormone.

Scientific Claim

Twelve months of tesamorelin treatment in obese adults with reduced growth hormone secretion does not significantly alter fasting glucose levels, 2-hour glucose during oral glucose tolerance test, fasting insulin concentrations, or insulin resistance measures (all P>0.10).

Original Statement

“Treatment with tesamorelin did not affect fasting glucose, 2-hour glucose with an OGTT, fasting insulin, or homeostasis model assessment of insulin resistance (all P > .10).”

From study:The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.

Evidence Quality Assessment

Claim Status

appropriately stated

Study Design Support

Design supports claim

Appropriate Language Strength

definitive

Can make definitive causal claims

Assessment Explanation

The RCT design supports definitive statements about no effect when P>0.10. The phrasing 'does not significantly alter' correctly reflects the null findings.

Evidence from Studies

Supporting (1)

The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.

Randomized Controlled Trial

Human

2014 Jan

Contradicting (0)

No contradicting evidence found

Source Study

The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.

Score: 61

DOI: 10.1210/jc.2013-3436

Similar Assertions

The drug didn’t make blood sugar or insulin levels better, so its benefits must come from somewhere else — likely directly on muscle energy production.

90%

Taking tesamorelin for a year makes IGF-I levels rise much more in obese people with low growth hormone than taking a dummy pill, with a clear difference between the two groups.

85%

Taking tesamorelin for a year makes the hormone IGF-I go up much more in obese people with low growth hormone compared to taking a sugar pill.

84%

After a year of treatment, tesamorelin didn't show a clear improvement in muscle energy recovery compared to a placebo in obese people with low growth hormone.

81%

In obese people with low growth hormone taking tesamorelin, the link between higher IGF-I and better muscle energy recovery is even stronger than in the whole group of participants.

80%